Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mass Screening | 16 | 2022 | 843 | 3.570 |
Why?
|
| Chlamydia Infections | 12 | 2021 | 41 | 2.510 |
Why?
|
| Algorithms | 13 | 2022 | 1196 | 2.310 |
Why?
|
| Dog Diseases | 9 | 2020 | 45 | 2.210 |
Why?
|
| Gonorrhea | 9 | 2021 | 50 | 2.190 |
Why?
|
| Bayes Theorem | 14 | 2022 | 307 | 2.050 |
Why?
|
| Communicable Diseases | 6 | 2021 | 50 | 1.830 |
Why?
|
| Data Interpretation, Statistical | 6 | 2019 | 329 | 1.530 |
Why?
|
| Biometry | 5 | 2019 | 72 | 1.260 |
Why?
|
| Proportional Hazards Models | 5 | 2022 | 792 | 1.210 |
Why?
|
| Regression Analysis | 9 | 2021 | 737 | 1.070 |
Why?
|
| Leiomyoma | 2 | 2018 | 28 | 1.070 |
Why?
|
| Buprenorphine | 2 | 2022 | 67 | 0.960 |
Why?
|
| Models, Statistical | 11 | 2019 | 448 | 0.960 |
Why?
|
| Antibodies, Bacterial | 4 | 2020 | 90 | 0.880 |
Why?
|
| Models, Theoretical | 3 | 2020 | 384 | 0.860 |
Why?
|
| Cotinine | 1 | 2022 | 40 | 0.840 |
Why?
|
| Support Vector Machine | 1 | 2022 | 15 | 0.810 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2019 | 51 | 0.810 |
Why?
|
| Drug Overdose | 1 | 2022 | 67 | 0.770 |
Why?
|
| Ehrlichia | 2 | 2020 | 6 | 0.760 |
Why?
|
| Opioid-Related Disorders | 2 | 2022 | 298 | 0.760 |
Why?
|
| Ehrlichiosis | 2 | 2020 | 15 | 0.750 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2021 | 53 | 0.740 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 26 | 0.740 |
Why?
|
| Anaplasma | 2 | 2017 | 6 | 0.730 |
Why?
|
| Anaplasmosis | 2 | 2017 | 6 | 0.730 |
Why?
|
| Nicotine | 2 | 2022 | 350 | 0.710 |
Why?
|
| Universities | 4 | 2022 | 191 | 0.700 |
Why?
|
| Dogs | 9 | 2020 | 490 | 0.640 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 10 | 0.610 |
Why?
|
| Humans | 45 | 2022 | 68618 | 0.600 |
Why?
|
| Risk Assessment | 3 | 2015 | 2007 | 0.590 |
Why?
|
| Models, Genetic | 1 | 2017 | 161 | 0.580 |
Why?
|
| Computer Simulation | 11 | 2022 | 706 | 0.570 |
Why?
|
| Genomics | 1 | 2017 | 168 | 0.560 |
Why?
|
| Health Status | 1 | 2018 | 429 | 0.510 |
Why?
|
| Substance-Related Disorders | 2 | 2022 | 1242 | 0.500 |
Why?
|
| Biomarkers | 8 | 2021 | 1593 | 0.470 |
Why?
|
| Seroepidemiologic Studies | 6 | 2020 | 41 | 0.450 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 16 | 0.440 |
Why?
|
| Poisson Distribution | 3 | 2019 | 85 | 0.430 |
Why?
|
| Genome-Wide Association Study | 3 | 2022 | 240 | 0.390 |
Why?
|
| United States | 12 | 2022 | 7367 | 0.390 |
Why?
|
| Probability | 3 | 2019 | 245 | 0.390 |
Why?
|
| Pets | 3 | 2019 | 10 | 0.380 |
Why?
|
| Students | 3 | 2022 | 233 | 0.370 |
Why?
|
| Monte Carlo Method | 3 | 2019 | 124 | 0.350 |
Why?
|
| Hepatitis B | 3 | 2022 | 42 | 0.350 |
Why?
|
| Dirofilariasis | 2 | 2019 | 6 | 0.310 |
Why?
|
| Lyme Disease | 2 | 2019 | 17 | 0.310 |
Why?
|
| Likelihood Functions | 4 | 2017 | 106 | 0.280 |
Why?
|
| Prevalence | 6 | 2021 | 1619 | 0.260 |
Why?
|
| Opiate Substitution Treatment | 2 | 2022 | 57 | 0.250 |
Why?
|
| Female | 15 | 2022 | 38074 | 0.240 |
Why?
|
| Infertility | 2 | 2016 | 26 | 0.240 |
Why?
|
| Nebraska | 3 | 2016 | 9 | 0.230 |
Why?
|
| Disease Outbreaks | 2 | 2021 | 83 | 0.230 |
Why?
|
| Pregnancy | 4 | 2018 | 2334 | 0.220 |
Why?
|
| Risk Factors | 6 | 2021 | 5731 | 0.220 |
Why?
|
| Viral Vaccines | 1 | 2022 | 17 | 0.210 |
Why?
|
| Opiate Alkaloids | 1 | 2022 | 6 | 0.210 |
Why?
|
| Dysentery | 1 | 2021 | 1 | 0.200 |
Why?
|
| Global Burden of Disease | 1 | 2021 | 4 | 0.200 |
Why?
|
| Forecasting | 3 | 2017 | 277 | 0.200 |
Why?
|
| RNA, Viral | 1 | 2021 | 93 | 0.190 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 106 | 0.190 |
Why?
|
| Chlamydia trachomatis | 1 | 2021 | 26 | 0.190 |
Why?
|
| Sensitivity and Specificity | 3 | 2021 | 1753 | 0.190 |
Why?
|
| Male | 12 | 2022 | 37321 | 0.190 |
Why?
|
| Climate | 2 | 2017 | 9 | 0.180 |
Why?
|
| Dirofilaria immitis | 2 | 2019 | 6 | 0.180 |
Why?
|
| Incidence | 4 | 2021 | 1603 | 0.180 |
Why?
|
| Genotype | 1 | 2022 | 786 | 0.180 |
Why?
|
| Animals | 10 | 2020 | 20881 | 0.180 |
Why?
|
| Analgesics, Opioid | 2 | 2022 | 498 | 0.170 |
Why?
|
| Biological Assay | 1 | 2020 | 88 | 0.170 |
Why?
|
| Biostatistics | 3 | 2017 | 43 | 0.170 |
Why?
|
| Sublingual Immunotherapy | 1 | 2018 | 1 | 0.160 |
Why?
|
| Tobacco Products | 1 | 2021 | 234 | 0.160 |
Why?
|
| Peanut Hypersensitivity | 1 | 2018 | 5 | 0.160 |
Why?
|
| Ireland | 2 | 2021 | 13 | 0.160 |
Why?
|
| Allergens | 1 | 2018 | 54 | 0.160 |
Why?
|
| Bias | 2 | 2017 | 148 | 0.150 |
Why?
|
| Oryza | 1 | 2017 | 12 | 0.150 |
Why?
|
| Population Density | 1 | 2017 | 18 | 0.150 |
Why?
|
| Smoking | 2 | 2022 | 1452 | 0.150 |
Why?
|
| South Carolina | 2 | 2021 | 2752 | 0.150 |
Why?
|
| Tobacco Use Disorder | 1 | 2021 | 432 | 0.140 |
Why?
|
| Ascaridoidea | 1 | 2016 | 1 | 0.140 |
Why?
|
| Ascaridida Infections | 1 | 2016 | 1 | 0.140 |
Why?
|
| Rodent Diseases | 1 | 2016 | 4 | 0.140 |
Why?
|
| Peromyscus | 1 | 2016 | 14 | 0.140 |
Why?
|
| Phenotype | 1 | 2019 | 947 | 0.140 |
Why?
|
| Epidemiologic Studies | 1 | 2016 | 33 | 0.140 |
Why?
|
| Machine Learning | 1 | 2018 | 170 | 0.140 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2016 | 12 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 561 | 0.130 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2015 | 13 | 0.130 |
Why?
|
| Iowa | 3 | 2020 | 33 | 0.130 |
Why?
|
| Artifacts | 1 | 2015 | 125 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 931 | 0.120 |
Why?
|
| Infertility, Female | 1 | 2013 | 25 | 0.110 |
Why?
|
| Tennessee | 1 | 2013 | 11 | 0.110 |
Why?
|
| Texas | 1 | 2013 | 92 | 0.110 |
Why?
|
| Pregnancy Trimester, First | 1 | 2013 | 43 | 0.110 |
Why?
|
| North Carolina | 1 | 2013 | 224 | 0.110 |
Why?
|
| Models, Biological | 1 | 2017 | 981 | 0.110 |
Why?
|
| Prisoners | 1 | 2012 | 50 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2013 | 285 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 100 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2013 | 453 | 0.090 |
Why?
|
| Logistic Models | 1 | 2012 | 1420 | 0.080 |
Why?
|
| Spatio-Temporal Analysis | 2 | 2019 | 28 | 0.080 |
Why?
|
| Adult | 3 | 2022 | 21403 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2018 | 7029 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2013 | 3705 | 0.060 |
Why?
|
| Neoplasms | 1 | 2015 | 1667 | 0.060 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 19 | 0.050 |
Why?
|
| Indonesia | 1 | 2021 | 11 | 0.050 |
Why?
|
| Disabled Persons | 1 | 2021 | 94 | 0.050 |
Why?
|
| Ehrlichia chaffeensis | 1 | 2020 | 3 | 0.050 |
Why?
|
| Appalachian Region | 1 | 2020 | 6 | 0.050 |
Why?
|
| Ehrlichia canis | 1 | 2020 | 7 | 0.040 |
Why?
|
| Biocompatible Materials | 1 | 2022 | 247 | 0.040 |
Why?
|
| Antigens, Helminth | 1 | 2019 | 1 | 0.040 |
Why?
|
| Hospitals, Animal | 1 | 2019 | 2 | 0.040 |
Why?
|
| Mississippi | 1 | 2019 | 11 | 0.040 |
Why?
|
| Zoonoses | 1 | 2019 | 12 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 55 | 0.040 |
Why?
|
| Child | 2 | 2022 | 6405 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 80 | 0.040 |
Why?
|
| Borrelia burgdorferi | 1 | 2019 | 11 | 0.040 |
Why?
|
| Arachis | 1 | 2018 | 8 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 955 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 58 | 0.040 |
Why?
|
| Linear Models | 1 | 2019 | 521 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 848 | 0.040 |
Why?
|
| Animals, Domestic | 1 | 2017 | 8 | 0.040 |
Why?
|
| Abortion, Spontaneous | 1 | 2017 | 17 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1553 | 0.040 |
Why?
|
| Culicidae | 1 | 2016 | 12 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 101 | 0.030 |
Why?
|
| Raccoons | 1 | 2016 | 2 | 0.030 |
Why?
|
| Oregon | 1 | 2016 | 7 | 0.030 |
Why?
|
| Topography, Medical | 1 | 2016 | 10 | 0.030 |
Why?
|
| Feces | 1 | 2016 | 88 | 0.030 |
Why?
|
| Sample Size | 1 | 2015 | 79 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 179 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 392 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2016 | 330 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2018 | 310 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1738 | 0.030 |
Why?
|
| Causality | 1 | 2013 | 82 | 0.030 |
Why?
|
| Aging | 1 | 2019 | 911 | 0.030 |
Why?
|
| Aged | 2 | 2021 | 14862 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 1056 | 0.030 |
Why?
|
| Young Adult | 1 | 2022 | 5717 | 0.020 |
Why?
|
| Middle Aged | 2 | 2021 | 21147 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 807 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2077 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 7277 | 0.020 |
Why?
|